Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Exponent management to meet virtually with Sidoti » 04:55
11/04/20
11/04
04:55
11/04/20
04:55
EXPO

Exponent

$72.54 /

+1.765 (+2.49%)

Virtual Meeting to be…

Virtual Meeting to be held on November 4 hosted by Sidoti.

ShowHide Related Items >><<
EXPO Exponent
$72.54 /

+1.765 (+2.49%)

EXPO Exponent
$72.54 /

+1.765 (+2.49%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$72.54 /

+1.765 (+2.49%)

EXPO Exponent
$72.54 /

+1.765 (+2.49%)

Earnings
Exponent sees Q4 revenue down 12%-15% amid COVID headwinds » 16:24
10/29/20
10/29
16:24
10/29/20
16:24
EXPO

Exponent

$71.59 /

-0.65 (-0.90%)

"While we continue…

"While we continue to see improvement across the business and have increased confidence in our ability to forecast our fourth quarter results, there remains uncertainty with regard to the course of the pandemic and related restrictions. As a reminder, the 13-week fourth quarter of this year will be compared with a 14-week fourth quarter of 2019. As a result, we will experience an 8% to 9% year-over-year revenue headwind due to the five less working days in the quarter this year. Further, due to the impact of continued business, travel and physical distancing restrictions caused by the COVID-19 pandemic, net revenues for the first three weeks of the fourth quarter of 2020 declined approximately 5% to 7% year-over-year. Assuming the activity levels of the first three weeks of the quarter continue and considering the impact of five less working days, we anticipate revenues before reimbursements to decline 12% to 15% in the quarter, and we expect EBITDA margin to decline 250 to 350 basis points from the 27.1% achieved in the fourth quarter of 2019. This would result in a mid-single digit decline in net revenue and 125 to 175 basis point decline in EBITDA margin for the 52-week fiscal year 2020 as compared to the 53-week fiscal year 2019. While there are opportunities for near-term improvement, there could also be further reduction to our revenues in the short term due to continued uncertainty," commented Richard Schlenker, Executive Vice President and Chief Financial Officer.

ShowHide Related Items >><<
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

Earnings
Exponent reports Q3 EPS 34c, consensus 31c » 16:22
10/29/20
10/29
16:22
10/29/20
16:22
EXPO

Exponent

$71.59 /

-0.65 (-0.90%)

Reports Q3 revenue…

Reports Q3 revenue $98.7M, consensus $92.8M. "We are pleased with the improvements that we have seen across our business and believe that our third quarter results demonstrate resilience in our model. While net revenues declined 2% year-over-year, we expanded EBITDA1 margin by 60 basis points. Companies and governments alike are adopting new ways to conduct business, from testing new procedures and protocols to designing new products and navigating new regulatory challenges. Clients continue to call on Exponent's multi-disciplinary teams for sound advice as they evolve, adapt and innovate," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "The demand for Exponent's interdisciplinary solutions is durable as society continues to raise its expectations for safety, health, sustainability, and reliability, and as technologies continue to increase in complexity. The COVID-19 pandemic has increased complexity in our system, and further challenged society's expectations for health and safety. Despite any risks or uncertainties related to the pandemic that may still be ahead of us, the bar will continue to be raised. Exponent is capitalizing on these persistent secular trends, and we remain focused on demonstrating our leadership through the same seriousness, intellectual rigor, and fact-based analysis that we have employed for over 50 years. These market drivers combined with Exponent's world-class team of subject-matter experts will fuel long-term growth," continued Dr. Corrigan.

ShowHide Related Items >><<
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

Earnings
Exponent reports Q3 EPS 34c, consensus 31c » 16:22
10/29/20
10/29
16:22
10/29/20
16:22
EXPO

Exponent

$71.59 /

-0.65 (-0.90%)

Reports Q3 revenue…

Reports Q3 revenue $98.7M, consensus $92.8M. "We are pleased with the improvements that we have seen across our business and believe that our third quarter results demonstrate resilience in our model. While net revenues declined 2% year-over-year, we expanded EBITDA1 margin by 60 basis points. Companies and governments alike are adopting new ways to conduct business, from testing new procedures and protocols to designing new products and navigating new regulatory challenges. Clients continue to call on Exponent's multi-disciplinary teams for sound advice as they evolve, adapt and innovate," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "The demand for Exponent's interdisciplinary solutions is durable as society continues to raise its expectations for safety, health, sustainability, and reliability, and as technologies continue to increase in complexity. The COVID-19 pandemic has increased complexity in our system, and further challenged society's expectations for health and safety. Despite any risks or uncertainties related to the pandemic that may still be ahead of us, the bar will continue to be raised. Exponent is capitalizing on these persistent secular trends, and we remain focused on demonstrating our leadership through the same seriousness, intellectual rigor, and fact-based analysis that we have employed for over 50 years. These market drivers combined with Exponent's world-class team of subject-matter experts will fuel long-term growth," continued Dr. Corrigan.

ShowHide Related Items >><<
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$71.59 /

-0.65 (-0.90%)

EXPO Exponent
$71.59 /

-0.65 (-0.90%)

Conference/Events
Exponent management to meet virtually with Sidoti » 12:25
10/29/20
10/29
12:25
10/29/20
12:25
EXPO

Exponent

$71.44 /

-0.8 (-1.11%)

Virtual Meeting to be…

Virtual Meeting to be held on November 4 hosted by Sidoti.

ShowHide Related Items >><<
EXPO Exponent
$71.44 /

-0.8 (-1.11%)

EXPO Exponent
$71.44 /

-0.8 (-1.11%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$71.44 /

-0.8 (-1.11%)

EXPO Exponent
$71.44 /

-0.8 (-1.11%)

Over a quarter ago
Earnings
Exponent reports Q2 EPS 31, consensus 25c » 16:23
07/30/20
07/30
16:23
07/30/20
16:23
EXPO

Exponent

$83.50 /

+1 (+1.21%)

Reports Q2 revenue…

Reports Q2 revenue $92.05M, consensus $88.34M. "We are pleased with the responsiveness of our employees and the adaptiveness of our company to today's uncertain environment. Clients continue to call upon Exponent to address their challenges and to evaluate their opportunities, despite the rapid change and unpredictability that the pandemic has infused into their operating plans. While net revenues declined 12% in the second quarter, the fundamentals of our business remain strong and we continue to operate in a position of financial strength. We ended the quarter with $190 million in cash, cash equivalents and short-term investments, no debt, and reiterated our intent to continue quarterly dividends," commented Catherine Corrigan, president and CEO.

ShowHide Related Items >><<
EXPO Exponent
$83.50 /

+1 (+1.21%)

EXPO Exponent
$83.50 /

+1 (+1.21%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$83.50 /

+1 (+1.21%)

EXPO Exponent
$83.50 /

+1 (+1.21%)

Hot Stocks
Exponent authorizes additional $45M share buyback » 16:42
05/29/20
05/29
16:42
05/29/20
16:42
EXPO

Exponent

$74.23 /

-0.46 (-0.62%)

In a regulatory 8-K…

In a regulatory 8-K filing, Exponent announced it has "authorized an additional $45M for share repurchases adding to the existing $30M available under the current authorization for repurchase. In total, the company now has $75M available to repurchase shares."

ShowHide Related Items >><<
EXPO Exponent
$74.23 /

-0.46 (-0.62%)

EXPO Exponent
$74.23 /

-0.46 (-0.62%)

05/13/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
EXPO Exponent
$74.23 /

-0.46 (-0.62%)

EXPO Exponent
$74.23 /

-0.46 (-0.62%)

Upgrade
Exponent upgraded to Buy from Neutral at Sidoti » 08:47
05/13/20
05/13
08:47
05/13/20
08:47
EXPO

Exponent

$62.78 /

-3.2 (-4.85%)

Sidoti analyst Marc…

Sidoti analyst Marc Riddick upgraded Exponent to Buy from Neutral with an unchanged price target of $80, telling investors that the company's increased accident and litigation related assignments will support his forecast for 21% EPS growth in 2021.

ShowHide Related Items >><<
EXPO Exponent
$62.78 /

-3.2 (-4.85%)

EXPO Exponent
$62.78 /

-3.2 (-4.85%)

04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
02/07/20 Cantor Fitzgerald
Exponent price target raised to $84 from $75 at Cantor Fitzgerald
EXPO Exponent
$62.78 /

-3.2 (-4.85%)

EXPO Exponent
$62.78 /

-3.2 (-4.85%)

On The Fly
Fly Insider: Fennec, Becton Dickinson among week's notable insider trades » 12:37
05/11/20
05/11
12:37
05/11/20
12:37
VOXX

VOXX

$5.76 /

+0.49 (+9.30%)

, MLHR

Herman Miller

$22.00 /

-1.6 (-6.78%)

, DFS

Discover

$41.12 /

-1.59 (-3.72%)

, FENC

Fennec

$7.47 /

+0.875 (+13.27%)

, BYD

Boyd Gaming

$18.00 /

+0.04 (+0.22%)

, ADVM

Adverum Biotechnologies

$19.57 /

-0.03 (-0.15%)

, AMZN

Amazon.com

$2,406.82 /

+28.1 (+1.18%)

, BDX

Becton Dickinson

$258.84 /

+4.55 (+1.79%)

, CRUS

Cirrus Logic

$74.65 /

-1.68 (-2.20%)

, EXPO

Exponent

$65.58 /

-0.505 (-0.76%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
VOXX VOXX
$5.76 /

+0.49 (+9.30%)

MLHR Herman Miller
$22.00 /

-1.6 (-6.78%)

03/19/20 Sidoti
Herman Miller downgraded to Neutral from Buy at Sidoti
02/03/20 Sidoti
Herman Miller upgraded to Buy on expected order bounceback at Sidoti
02/03/20 Sidoti
Herman Miller upgraded to Buy from Neutral at Sidoti
10/07/19 Raymond James
Raymond James steps away from three office furniture stocks
DFS Discover
$41.12 /

-1.59 (-3.72%)

04/27/20 JMP Securities
Discover price target lowered to $48 from $92 at JMP Securities
04/24/20 Deutsche Bank
Discover price target lowered to $55 from $72 at Deutsche Bank
04/13/20 Deutsche Bank
Discover price target lowered to $72 from $95 at Deutsche Bank
04/08/20 Wells Fargo
Discover price target lowered to $53 from $88 at Wells Fargo
FENC Fennec
$7.47 /

+0.875 (+13.27%)

BYD Boyd Gaming
$18.00 /

+0.04 (+0.22%)

04/29/20 Deutsche Bank
Boyd Gaming price target lowered to $22 from $42 at Deutsche Bank
04/29/20 Union Gaming
Boyd Gaming downgraded to Hold from Buy at Union Gaming
04/27/20 Nomura
Nomura sees 'attractive upside' in Boyd and Penn National as casinos reopen
04/27/20 Nomura
Boyd, Penn offer 'attractive upside' upon reopening, says Nomura Instinet
ADVM Adverum Biotechnologies
$19.57 /

-0.03 (-0.15%)

05/05/20 Truist
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 Truist
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
03/16/20 SVB Leerink
SVB Leerink bullish on Adverum Biotechnologies, initiates with an Outperform
AMZN Amazon.com
$2,406.82 /

+28.1 (+1.18%)

05/11/20 B. Riley Securities
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
05/07/20 Piper Sandler
Fastly price target raised to $31 from $27 at Piper Sandler
05/06/20 China Renaissance
Amazon.com price target raised to $2,162 from $1,850 at China Renaissance
05/05/20 Stifel
Stifel downgrades Wayfair to Sell on return of Amazon competition
BDX Becton Dickinson
$258.84 /

+4.55 (+1.79%)

04/08/20 Wells Fargo
Becton Dickinson price target lowered to $270 from $279 at Wells Fargo
03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/07/20
Fly Intel: Top five analyst downgrades
CRUS Cirrus Logic
$74.65 /

-1.68 (-2.20%)

05/05/20 Susquehanna
Cirrus Logic price target raised to $84 from $82 at Susquehanna
05/04/20 KeyBanc
Apple cautious iPhone outlook likely a headwind for chip suppliers, says KeyBanc
03/31/20
upgraded Fly Intel: Top five analyst upgrades
03/31/20 BofA
Cirrus Logic double-upgraded to Buy from Underperform at BofA
EXPO Exponent
$65.58 /

-0.505 (-0.76%)

04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
02/07/20 Cantor Fitzgerald
Exponent price target raised to $84 from $75 at Cantor Fitzgerald
Earnings
Exponent reports Q1 EPS 42c, consensus42c » 16:10
04/30/20
04/30
16:10
04/30/20
16:10
EXPO

Exponent

$70.61 /

-1.06 (-1.48%)

Reports Q1 revenue $99M,…

Reports Q1 revenue $99M, consensus $102.63M Exponent's fundamentals are sound and our market drivers are strong, despite uncertainties surrounding how and over what timeframe each region will relax business restrictions and physical distancing requirements. Clients continue to retain Exponent for our scientific expertise and sound advice, but the rate of new project engagements has slowed. With our talented workforce intact, we are well-positioned to execute on paused work and the anticipated acceleration of new work as business restrictions are eased. "The COVID-19 pandemic has caused revenues for the first three weeks of the second quarter to decline approximately 15% to 20% as compared to the same period last year. As business restrictions continue, there could be further reduction to our revenues in the short term," commented Richard Schlenker, Executive Vice President and Chief Financial Officer. "We cannot reliably provide revenue and earnings guidance at this time due to the high degree of uncertainty surrounding business, travel and physical distancing restrictions

ShowHide Related Items >><<
EXPO Exponent
$70.61 /

-1.06 (-1.48%)

04/09/20 Sidoti
Exponent downgraded to Neutral from Buy at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
03/19/20 Sidoti
Exponent upgraded to Buy from Neutral at Sidoti
02/07/20 Cantor Fitzgerald
Exponent price target raised to $84 from $75 at Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.